Skip to main content

Table 3 Univariate and multivariate analyses of clinicopathological characteristics of patients with hepatocellular carcinoma for OS

From: The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE

Parameter

Patient (n = 117)

OS

Univariate

P-value

Multivariate

P-value

HR (95%CI)

Age (y)

  < 60

49

   

  ≥ 60

68

0.669

  

Sex

 Male

96

   

 Female

21

0.13

  

Operation mode

 RFA + TACE

38

   

 MWA + TACE

79

0.77

  

Hepatectomy before treatment

 YES

25

   

 NO

92

0.237

  

Cirrhosis

 YES

80

   

 NO

37

0.12

  

ALB (g/l)

  < 35

13

   

  ≥ 35

104

0.057

  

AFP (ng/ml)

  < 200

87

   

  ≥ 200

30

0.015*

0.015*

1.961(1.140–3.374)

AST/ALT ratio

  ≤ 0.89

32

   

  > 0.89

85

0.005*

0.039*

2.075(1.039–4.145)

Tumor numbers

  < 3

86

   

  ≥ 3

31

 < 0.001*

 < 0.001*

3.074(1.832–5.160)

Tumor maximum diameter(mm)

  < 50

106

   

  ≥ 50

11

0.01*

0.22

 

BCLC stage

 A

86

   

 B

31

 < 0.001*

0.891

 

Child–Pugh grades

 A

113

   

 B

4

0.156

  
  1. OS overall survival, RFA radiofrequency ablation, TACE transarterial chemoembolization, MWA microwave ablation, ALB albumin, AFP alpha fetoprotein, AST aspartate transaminase, ALT alanine transaminase, BCLC Barcelona Clinic Liver Cancer
  2. *Data are statistically significant results